News

Filter

Current filters:

Novartis

1 to 9 of 3642 results

UK doctors call for approval of off-label use of Avastin for wet-AMD

UK doctors call for approval of off-label use of Avastin for wet-AMD

25-02-2015

Doctors in the UK are calling on health ministers and NHS England to intervene to make Swiss pharma giant…

AvastinBiotechnologyHealthcareLucentisNovartisOphthalmicsPricingRegulationRocheUK

Federal Trade Commission puts conditions on Novartis acquisition of GSK oncology portfolio

Federal Trade Commission puts conditions on Novartis acquisition of GSK oncology portfolio

24-02-2015

The US Federal Trade Commission has put conditions on the proposed acquisition by Novartis of GlaxoSmithKline’s…

Array BioPharmaGSKLegalMergers & AcquisitionsNovartisOncologyPharmaceuticalRegulationResearchUSA

US FDA approves Novartis’ Farydak, the first HDAC inhibitor for MM patients

24-02-2015

The US Food and Drug Administration yesterday approved Swiss pharma giant Novartis’ Farydak (panobinostat,…

FarydakNovartisOncologypanobinostatPharmaceuticalRegulationUSA

Novartis' heart failure drug LCZ696 granted FDA priority review

Novartis' heart failure drug LCZ696 granted FDA priority review

14-02-2015

The US Food and Drug Administration has granted priority review designation for combination pill LCZ696…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationsacubitrilUSAvalsartan

Vaccines a $25.5 billion business in 2014; report

Vaccines a $25.5 billion business in 2014; report

13-02-2015

Vaccines are a big business, and a growing business, says health care market researcher Kalorama Information,…

GlaxoSmithKlineMarkets & MarketingMerck & CoNovartisPfizerPharmaceuticalSanofiVaccines

Further approvals for ThromboGenics’ Jetrea

12-02-2015

Belgian biotech company ThromboGenics, which is focused on developing and commercializing innovative…

AlconArgentinaBiotechnologyIsraelJetreaNovartisOphthalmicsRegulationThromboGenics

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Could there be a Gleevec for brain cancer?

Could there be a Gleevec for brain cancer?

10-02-2015

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid…

BiotechnologyGleevecNeurologicalNovartisResearch

1 to 9 of 3642 results

COMPANY SPOTLIGHT

Menarini

Back to top